USPTO Patent Application: Medicament Delivery Device Dosage Adjustment

ChangeBridge: Patent Apps - Health Informatics (G16H)

Detected March 26th, 2026

Summary

The USPTO has published a patent application detailing a medicament delivery device that adjusts dosages based on a user's menstrual cycle phase. This technology aims to improve blood glucose control for users by reducing the risk of hyperglycemia and hypoglycemia.

View original document View source feed page

What changed

This document is a USPTO patent application (US20260083912A1) for a medicament delivery device that dynamically adjusts dosages based on the user's menstrual cycle phase. The application specifically mentions controlling blood glucose concentrations using medicaments like insulin, glucagon, and GLP-1 agonists, with the goal of reducing excursions and minimizing risks of hyperglycemia and hypoglycemia.

As this is a patent application, it does not impose immediate regulatory requirements or compliance deadlines on regulated entities. However, it signals potential future technological advancements in diabetes management and personalized medicine. Companies involved in developing or manufacturing insulin pumps, continuous glucose monitors, or related diabetes management technologies should be aware of this patent filing as it may influence future product development and intellectual property landscapes in the health informatics sector.

Source document (simplified)

← USPTO Patent Applications

ADJUSTMENT OF MEDICAMENT DELIVERY BY A MEDICAMENT DELIVERY DEVICE BASED ON MENSTRUAL CYCLE PHASE

Application US20260083912A1 Kind: A1 Mar 26, 2026

Inventors

Rangarajan NARAYANASWAMI

Abstract

Exemplary embodiments account for differing needs of a user over the menstrual cycle of the user to better control the blood glucose concentration of the user. The exemplary embodiments may be realized in control systems for medicament delivery devices that deliver medicaments, such as medicaments that regulate blood glucose concentration levels. Examples of such medicaments that regulate blood glucose concentration levels include insulin, glucagon, and glucagon peptide-1 (GLP-1) agonists. The exemplary embodiments are able to better tailor the dosages of the medicament delivered to the user with the medicament delivery device to reduce the risk of hyperglycemia and hypoglycemia and help reduce blood glucose concentration excursions.